As resistant mechanisms, NTRK1 G595R (solvent front) and G667S (xDFG motif) mutations were detected in a TPR‐NTRK1 fusion‐positive lung cancer patient who acquired resistance to larotrectinib (Figure 2B,C).73 This evidence concerns the gene NTRK1 and lung carcinoma.